Sernova (TSE:SVA) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sernova Corp’s Phase I/II clinical trial shows promising results with their Cell Pouch system successfully enabling sustained insulin independence in patients with type 1 diabetes, with healthy, functioning islets seen more than five years post-transplant. The new data, indicating no detrimental tissue effects and the potential for a functional cure, brings hope to those affected by the disease.
For further insights into TSE:SVA stock, check out TipRanks’ Stock Analysis page.
